Sort
40,608 grants matching “prostate cancer”
Brucella epitope recognition by CD8+ T cells
$367,500Gary A Splitter · University Of Wisconsin-Madison · R01 · FY2009 · AI
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer
$367,422Karen E Knudsen · Thomas Jefferson University · R01 · FY2017 · CA
EFFECTS OF LOW-DOSE CADMIUM ON PROSTATE CELLS
$367,420Henry M. Jackson Fdn For The Adv Mil/Med · R21 · FY2000 · AT
Prevention and Treatment of Impotence
$367,401Tom F Lue · University Of California, San Francisco · R37 · FY2010 · DK
Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial
$367,352Phuoc T. Tran · University Of Maryland Baltimore · U54 · FY2022 · CA
Novel Insights in the regulation of HIF1alpha Stability
$367,335Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · CA
Clinical and Analytical Validation of Cancer Biomarkers
$367,325Daniel W Chan · Johns Hopkins University · U24 · FY2014 · CA
Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue and BPH Therapy
$367,304Aria F Olumi · Massachusetts General Hospital · R01 · FY2013 · DK
Hybrid Intelligence for Trustable Diagnosis And Patient Management of Prostate Cancer (HIT-PIRADS)
$367,277Ulas Bagci · Northwestern University At Chicago · U01 · FY2024 · CA
Therapeutic targeting Wnt5A signaling for advanced prostate cancer
$367,236Allen C Gao · University Of California At Davis · R01 · FY2025 · CA
Eye Disease in a Trial of Selenium and Vitamin E
$367,203Brigham And Women'S Hospital · R01 · FY2004 · EY
Inflammation and cancer treatment
$367,137David Wink · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Project 1: Targeting the MYC Pathway in Prostate Cancer
$367,114Sarki A. Abdulkadir · Northwestern University At Chicago · P50 · FY2024 · CA
Phage Display and Prostate Neoplasia Progression
$367,088Emory University · R33 · FY2004 · CA
Immunogenomic determinants of response and resistance to neoadjuvant anti-PD-1 in resectable NSCLC
$367,087Kellie Nicole Smith · Johns Hopkins University · R37 · FY2023 · CA
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer
$367,087Jun Luo · Johns Hopkins University · R01 · FY2023 · CA
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer
$367,087Jun Luo · Johns Hopkins University · R01 · FY2022 · CA
Translational Molecular and Cellular Imaging Technologies for Prostate Tumor Pathology
$367,076Rohit Bhargava · University Of Illinois At Urbana-Champaign · R33 · FY2017 · CA
Tyrosine Phosphorylation in Integrin Signaling
$367,036David D Schlaepfer · Scripps Research Institute, The · R01 · FY2006 · CA
MR GUIDED FOCUSED ULTRASOUND ABLATION OF PROSTATE CANCER
$367,011General Electric Global Research Ctr · R33 · FY2002 · CA
Project 1: Determining and Exploiting Mechanisms of AR-Mediated Suppression of Cell Proliferation and Survival
$366,979Peter S Nelson · Beth Israel Deaconess Medical Center · P01 · FY2021 · CA
Project 1: Determining and Exploiting Mechanisms of AR-Mediated Suppression of Cell Proliferation and Survival
$366,979Peter S Nelson · Beth Israel Deaconess Medical Center · P01 · FY2020 · CA
Phase III Study of Donepezil in the Irradiated Brain
$366,962Stephen R Rapp · Wake Forest University Health Sciences · R01 · FY2007 · NR
Targeting androgen receptor nuclear localization in prostate cancer
$366,962Zhou Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
DNA Repair Pathways Choice to Regulate Therapeutic Resistance in Cancer Cells
$366,954Zihua Gong · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · CA